Expression and clinical significance of H-caldesmon in gastrointestinal stromal tumor: is it a specific marker for myogenic differentiation?
GIST
H-caldesmon
differential diagnosis
Journal
International journal of clinical and experimental pathology
ISSN: 1936-2625
Titre abrégé: Int J Clin Exp Pathol
Pays: United States
ID NLM: 101480565
Informations de publication
Date de publication:
2019
2019
Historique:
received:
20
04
2019
accepted:
22
05
2019
entrez:
15
1
2020
pubmed:
15
1
2020
medline:
15
1
2020
Statut:
epublish
Résumé
To investigate the expression and clinical significance of H-caldesmon which is considered a myogenic marker in GIST. The clinical information of 105 patients diagnosed with GIST was obtained from Yantai Yuhuangding Hospital and Rambam Health Care Campus. Morphology, the results of immunohistochemical staining and available molecular detection were reviewed. The expression of H-caldesmon was detected for each specimen by immunohistochemical staining. Comparative analysis was carried out between H-caldesmon expression and clinicopathologic parameters. H-caldesmon was expressed in all patients with GIST including tumors outside the gastrointestinal tract and with CD117-negative expression. Although the pattern of expression was different, the positive rate in our study group was 100%. There was no statistically difference between H-caldesmon expression and parameters such as gender, age, location, morphology, risk, immunologic markers, and molecular mutation. H-caldesmon is expressed positively in GIST and might not be a specific marker for smooth muscle and associated tumors. GIST outside the gastrointestinal tract or with CD117-negative expression should not be misdiagnosed assmooth muscle tumor because of the positive expression of H-caldesmon in the differential diagnosis. Comprehensive analysis combined with other immunological markers and molecular detection is needed.
Types de publication
Journal Article
Langues
eng
Pagination
2566-2571Informations de copyright
IJCEP Copyright © 2019.
Déclaration de conflit d'intérêts
None.
Références
Eur Biophys J. 2016 Dec;45(8):861-867
pubmed: 27678004
Cancer Res. 2001 Nov 15;61(22):8118-21
pubmed: 11719439
Proc Natl Acad Sci U S A. 1987 Dec;84(24):9049-53
pubmed: 3321066
Hum Pathol. 2002 Jun;33(6):669-76
pubmed: 12152168
Mod Pathol. 1998 Aug;11(8):728-34
pubmed: 9720500
Pathology. 2018 Apr;50(3):358-361
pubmed: 29490873
Arch Pathol Lab Med. 2006 Oct;130(10):1466-78
pubmed: 17090188
Pathol Int. 1999 Sep;49(9):786-98
pubmed: 10504550
Am J Surg Pathol. 2015 Jul;39(7):922-30
pubmed: 25970686
Gastric Cancer. 2003;6(1):39-48
pubmed: 12673425
Cell Calcium. 2018 Nov;75:89-100
pubmed: 30205293
J Clin Oncol. 2017 Feb 10;35(5):523-528
pubmed: 28029307
Histopathology. 2018 Jan;72(2):359-361
pubmed: 28833394
Am J Surg Pathol. 2006 Apr;30(4):463-9
pubmed: 16625092